SwePub
Sök i LIBRIS databas

  Extended search

WFRF:(Baniel Jack)
 

Search: WFRF:(Baniel Jack) > Cardiovascular Prot...

  • Lifshitz, KarinIsrael Defense Forces (author)

Cardiovascular Proteomics : A Post Hoc Analysis from a Phase II Randomized Clinical Trial Comparing GnRH Antagonist vs GnRH Agonist among Men with Advanced Prostate Cancer

  • Article/chapterEnglish2021

Publisher, publication year, extent ...

  • 2021
  • 8 s.

Numbers

  • LIBRIS-ID:oai:lup.lub.lu.se:6e95c2e4-3bb9-408a-b324-2d7a76520807
  • https://lup.lub.lu.se/record/6e95c2e4-3bb9-408a-b324-2d7a76520807URI
  • https://doi.org/10.1097/JU.0000000000001879DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:art swepub-publicationtype
  • Subject category:ref swepub-contenttype

Notes

  • PURPOSE: Recent studies demonstrated reduced cardiovascular (CV) risk with gonadotropin-releasing hormone (GnRH) antagonist, yet the underlying mechanism remains undetermined. The objective of this study was to examine longitudinal changes over time in established CV related proteins among men treated with GnRH agonists vs GnRH antagonist. MATERIALS AND METHODS: We performed a proteomics analysis of serum samples collected during a phase II randomized study among 80 men with advanced prostate cancer and preexisting CV disease who were randomized to receive a GnRH agonist (39) or GnRH antagonist (41) for 1 year. Serum samples were collected at baseline and at 3, 6 and 12 months following treatment, and analyzed levels of 188 proteins using the CV panel II and III of the Olink Multiplex platform (Olink Proteomics AB, Uppsala, Sweden). We fitted a linear mixed effects model to assess evidence of a treatment effect across CV related protein values. This included terms for treatment arm, protein levels and time-by-treatment interaction. Results were corrected for multiple testing using the Benjamini-Hochberg method. RESULTS: The CV proteomics analysis included 283 samples from 78 subjects. We identified 5 proteins with distinct patterns over time depending on study arm: human chitotriosidase, macrophage receptor with collagenous structure, cathepsin D, superoxide dismutase 2 and hydroxyacid oxidase 1. All 5 are associated with plaque stability and demonstrated an increased level among subjects in the GnRH antagonist arm compared to agonist. CONCLUSIONS: We compared longitudinal changes in CV proteins among men using androgen deprivation therapy. Our results support a direct protective effect of GnRH antagonist on plaque stability rather than a hazardous consequence of GnRH agonists on plaque rupture. This is a hypothesis generating study, and requires further confirmation.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Ber, YaaraRabin Medical Center (author)
  • Shenhar, ChenRabin Medical Center (author)
  • Nillson, JanLund University,Lunds universitet,Kardiovaskulär forskning - immunitet och ateroskleros,Forskargrupper vid Lunds universitet,Cardiovascular Research - Immunity and Atherosclerosis,Lund University Research Groups,Skåne University Hospital(Swepub:lu)medf-jni (author)
  • Peer, AvivitTechnion - Israel Institute of Technology (author)
  • Rosenbaum, EliRabin Medical Center (author)
  • Baniel, JackTel-Aviv University,Rabin Medical Center (author)
  • Kedar, DanielRabin Medical Center (author)
  • Ben Zadok, Osnat ItzhakiRabin Medical Center,Tel-Aviv University (author)
  • Margel, DavidRabin Medical Center (author)
  • Israel Defense ForcesRabin Medical Center (creator_code:org_t)

Related titles

  • In:The Journal of urology206:4, s. 952-9591527-3792

Internet link

Find in a library

To the university's database

Search outside SwePub

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view